ProShares Ultra Bloomberg Natural Gas ETF vs Medpace Holdings Inc — how do they compare? ProShares Ultra Bloomberg Natural Gas ETF trades at $20.68, while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Medpace Holdings Inc is trading nearer its 52-week high, ProShares Ultra Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| BOIL | MEDP | |
|---|---|---|
Sector | Leveraged / Inverse | Technology |
52-Week High | $87.24 | $620.59 |
52-Week Low | $18.74 | $393.42 |
Market Cap | — | $16.90B |
Enterprise Value | — | $16.52B |
Signals from Pluang's Aura AI — not financial advice
BOIL trades at $20.73, showing minimal daily movement with a 0.1% gain. Technical indicators signal a bearish trend with moving averages in sell territory, though oscillators remain neutral. The stock faces resistance at $21 with support at $20. Recent corporate actions include a 1:2 stock split scheduled for May 28, 2026. Natural gas market volatility and weather-dependent demand continue to influence price movements.
The outlook remains cautious given bearish technical signals and natural gas market uncertainty. Investment opportunities exist for tactical traders during volatility spikes, but risks include weather-dependent demand fluctuations and production increases. The stock split may improve liquidity but doesn't alter fundamental valuation. Investors should monitor EIA storage reports and weather forecasts as key catalysts.
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
BOIL is a leveraged ETF that seeks to provide two times (2x) the daily performance of the Bloomberg Natural Gas Subindex. It uses futures contracts to offer magnified exposure to natural gas price movements.
Read more on BOIL →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →